Published: February 10, 2006
U.S. MedSys Division, New England Orthotic and Diabetic Shoe Company to Participate in Major Trade Show
HASBROUCK HEIGHTS, N.J., Feb. 10, 2006 (PRIMEZONE) -- U.S. MedSys Corp. (The "Company") is pleased to announce that its manufacturing division, New England Orthotic and Diabetic Shoe Company, ("NEODS") will be exhibiting its line shoes and orthotics at the World Shoe Association Exposition from February 10 through February 13, 2006 at the Sands Expo and Convention Center in Las Vegas.
The World Shoe Association Exposition attracts more than 1,600 exhibitors and 34,000 professional and buyers from around the world.
This marks the first major showing of NEODS men and women's comfort and diabetic shoe lines, as well as its three-quarter orthotic insert line.
Located in Wilton, Maine, all of NEODS products are made in the USA and include shoe sizes up to 18 and 6e.
About U.S. MedSys Corp.
U.S. MedSys Corp is a medical network developer, marketing and distribution organization, which provides support services and medical technology to the healthcare industry. U.S. MedSys Corp. is focusing on its core competencies in healthcare delivery, network development and marketing. The Company's purpose is to create a total platform that can be presented to healthcare providers as a means for Healthcare Administrators to cut costs without sacrificing quality of care to its membership. The UMSY business network consists of Global Medical Direct, a provider of sales, marketing and distribution of self-management products and services to patients with diabetes, PMC/Footcare, LLC, PMC Occular, LLC and New England Orthotic and Diabetic Shoe Company (NEODS), which has been established to manufacture and market semi-custom orthotics, diabetic shoes and insoles. The company also markets its proprietary wound care program to the nursing home market.
Safe Harbor Forward-Looking Statements;
This press release may contain "forward-looking statements" within the meaning of section 27A of the 1933 Securities Act and Section 21E of the Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the company to execute its plans. By making forward-looking statements, the company can give no assurances that the transactions described in this release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.
CONTACT: U.S. MedSys Corp.
Anthony Rubino
201-288-3082
Search News
